News

DP Clinical 31 Miles Walking Challenge

ROCKVILLE, MD – November 7, 2023 – THANK YOU to everyone who participated in our 31 Miles in 31 Days Walking Challenge. DPC had an amazing showing of support for Parkinson’s Research. Here are the results:

  • Total # of Walkers: 21
  • Total # of Miles Walked: 694.10
  • 694.10 miles equates to 43,978,176 steps

Well done, DPC.

DP Clinical Facilitating Roundtable at OCT New England

ROCKVILLE, MD – October 12, 2023 – DP Clinical will be hosting and facilitating an interactive roundtable discussion at the upcoming Outsourcing in Clinical Trials New England with Q&A on topics such as:

  • CRO Selection Process
  • Best Practices for Writing an RFP
  • Feasibility – How Much Validation is Enough?
  • Accountability, Governance, and Strategic Guidance Differences Between Small and Large CROs

If you’re attending OCT-New England and would like to discuss what you’ve heard during the conference, please plan on participating in our Roundtable Discussion November 2, 2023, at 3:45 p.m.

DP Clinical President and CEO selected as Fellow of the American Spinal Injury Association

ROCKVILLE, MD – October 10, 2023 – Devinder Poonian, President and CEO of DP Clinical, has been selected as a Fellow of the American Spinal Injury Association (FASIA) in recognition of distinguished accomplishments within the fields of spinal cord injury research, clinical practice, education, and advocacy, and for a longstanding membership of service to the society.  Ms. Poonian will be honored during ASIA’s 2024 Annual Scientific Meeting in Puerto Rico.

DP Clinical Congratulates NervGen Pharma on its First Subject Dosed in Spinal Cord Injury Clinical Trial

ROCKVILLE, MD – October 3, 2023 – DP Clinical congratulates NervGen Pharma Corp., a biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, on dosing its first subject in the Company’s landmark Phase 1b/2a clinical trial for its proprietary lead compound, NVG-291, in individuals with spinal cord injury (SCI). Read more at NervGen Pharma Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury – NervGen Pharma.

DP Clinical Congratulates MediWound on the US Commercialization of NexoBrid® for the Treatment of Severe Thermal Burns

ROCKVILLE, MD – September 28, 2023 – MediWound Ltd., an Israeli biopharmaceutical company, announced the US commercial availability of NexoBrid® in adults with severe thermal burns – a first step in the product becoming the new standard of care for eschar removal. MediWound has partnered with DP Clinical, a full-service CRO located in Rockville, Maryland, since 2014 to conduct its US adult studies for this product.  “The commercialization of NexoBrid® in the US provides a treatment that can reduce the need for surgical excision and subsequent skin grafting, reduces inflammation and burn progression, and mitigates infections – all critical to the recovery of patients with deep partial and/or full-thickness thermal burns,” stated Devinder Poonian, DP Clinical’s CEO. “We are proud of our part in this product’s development and are confident NexoBrid® will have a significant positive impact on the way severe burns are treated.” Ms. Poonian continued.

DP Clinical Moderating “The State of Clinical Trials” at 2023 ASIA Meeting

ROCKVILLE, MD – December 13, 2022 – Isa McClure, Clinical Project Manager and James (Jim) Hamer, Director, Spinal Cord Injury (SCI) programs will be moderating a breakout session at the upcoming American Spinal Injury Association (ASIA) April 17 – 19, 2023.   DP Clinical is a proud partner of ASIA who, in 2023, celebrates 50 years of work advancing the care, education, and research to improve the lives of people affected by spinal cord injury.

DP Clinical Recognized by Canada’s Strategic Science Fund

ROCKVILLE, MD – October 26, 2022 – James (Jim) Hamer, Director, Spinal Cord Injury (SCI) Programs was recently recognized by the Canadian Government for his work with the Strategic Science Fund (SSF).  Jim served as a Technical Reviewer for the country’s new SSF program.  This program was implemented to improve the effectiveness of federal investments used to support third-party science and research organizations.  We congratulate Jim on being recognized as an expert in the field of SCI.  DP Clinical has proven experience conducting clinical programs in the SCI space. If you are looking for assistance with your next SCI clinical trial, contact DP Clinical at info@dpclinical.com.

DP Clinical Welcomes Timothy Urschel as Vice President, Regulatory Affairs/Quality Assurance

ROCKVILLE, MD – June 10, 2021 – DP Clinical, Inc., a Contract Research Organization (CRO) specializing in dermatology, infectious disease, neuroscience, oncology, and ophthalmology Phase I-III clinical programs; continues its growth with the addition of Tim Urschel as Vice President, Regulatory Affairs/Quality Assurance. Mr. Urschel joined the DP Clinical team in October 2020 and brings more than 25 years of experience in regulatory affairs and GxP quality assurance including regulatory GxP compliance and development of quality management systems in both GCP and GMP environments. His broad range of experience includes the development of regulatory strategies including NDAs, INDs, Annual Reports, Orphan Drug Applications, CTAs, and MAA applications.

Prior to joining DP Clinical, Mr. Urschel worked for Onconova Therapeutics, Inc. as a Vice President, Quality Assurance, where he was responsible for the overall quality assurance function to ensure compliance with federal and local regulations using a risk-based approach.

Mr. Urschel holds a BS degree in Medicinal Chemistry from the State University of New York at Buffalo and an MBA in Pharmaceutical Studies from Fairleigh-Dickinson University, Rutherford, New Jersey, and is a certified Quality Assurance Professional from the Society of Quality Assurance (SQA), an Accredited Clinical Researcher.

“Tim has touched every aspect of clinical research working at CROs, biotech, and pharmaceutical companies and is a proven leader in managing and building regulatory affairs and quality assurance functions in a competitive industry. We are excited to have him spearhead this initiative at DP Clinical,” stated Devinder Poonian, President and CEO.

Events

Come meet the DP Clinical team at the following conferences: